TrialPloS one2022

The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.

Riham M Karkeet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.